Ventrus Biosciences (VTUS)
Ventrus Biosciences Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these VTUS related companies
VTUS News
$KERX solid volume pushing higher so far. $amrn $arna holding up. $vtus looking to add
about a day ago by ITradeforMe
about a day ago by ITradeforMe
Ventrus to Present at the Jefferies 2012 Global Healthcare Conference $VTUS http://stks.co/428w
about 2 days ago by ventrusbio
about 2 days ago by ventrusbio
$VTUS undervalued stock that can gain upto 200% in a year, great ph3 results announced recently, target 29$ $$
about 3 days ago by peterumble
about 3 days ago by peterumble
$VTUS up 9% from 10.01 when tweeted buying in morning, target 29$, get long this co., posted
about 11 days ago by peterumble
about 11 days ago by peterumble
RT @Singe: but $VTUS chart looks like crap and $VVUS chart is slowly on way to 25 where it could break.//Buy at bottom not at top #MONEY $$
about 11 days ago by peterumble
about 11 days ago by peterumble
@peterumble but the $VTUS chart looks like crap and the $VVUS chart is slowly on the way to 25 where it could break out this time.
about 11 days ago by Singe
about 11 days ago by Singe
$VTUS adding again as stock is damn cheap at 10 after positive ph 3 results last week, avg price target is 29$, 300% upside $$
about 11 days ago by peterumble
about 11 days ago by peterumble
$AMRN Marine 889 patent prosecution update http://stks.co/3tFJ $ARRY $GALE $VTUS $PFE $KERX
about 14 days ago by imhobutdydd
about 14 days ago by imhobutdydd
@Szw go read up FDA approval process. $vtus hasn't even submitted an NDA yet. That means at this point it'll be a ~year if they apply now
about 14 days ago by elysian
about 14 days ago by elysian
$AMRN Marine 889 patent prosecution update http://stks.co/3soe $ARRY $GALE $VTUS $PFE $KERX
about 15 days ago by imhobutdydd
about 15 days ago by imhobutdydd
Ventrus to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 15, 7:00AM GlobeNewswire
May 15, 7:00AM GlobeNewswire
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
Ventrus to Present at the 37th Annual Deutsche Bank Health Care Conference
May 01, 8:30AM GlobeNewswire
May 01, 8:30AM GlobeNewswire
Cantor Fitzgerald Starts Ventrus Biosciences (VTUS) at Buy; N-T Binary Play
Apr 05, 7:11AM Street Insider
Apr 05, 7:11AM Street Insider
Ventrus Announces Two Studies Addressing Hemorrhoid Disease to be Presented at Digestive Disease Week Conference
Mar 08, 8:30AM GlobeNewswire
Mar 08, 8:30AM GlobeNewswire
Ventrus to Present at Cowen and Company 32nd Annual Health Care Conference
Feb 28, 8:30AM GlobeNewswire
Feb 28, 8:30AM GlobeNewswire
Ventrus BioSciences (VTUS) Publicizes Prior Phase 2b Study on the Safety and Efficacy of Iferanserin
Jan 13, 3:01PM Street Insider
Jan 13, 3:01PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VTUS | 9.86 | -0.25 | -2.47% | 125.47M |
| VTROD | 1.30 | +0.00 | +0.00% | |
| VTR | 57.09 | -1.73 | -2.94% | 16.99B |
| VTNC | 6.58 | -0.42 | -6.00% | 114.31M |
| VTN | 15.92 | -0.04 | -0.25% | |
| VTJ | 18.17 | +0.07 | +0.39% | |
| VTI | 65.93 | -1.40 | -2.08% | |
| VTA | 11.52 | -0.05 | -0.43% | |
| VT | 42.65 | -0.79 | -1.82% | |
| VSTA | 2.80 | -0.19 | -6.35% |
